Article Correctness Is Author's Responsibility: Oncotarget: Both BRCA1-wild type and -mutant triple-negative ****** cancers show

(Impact Journals LLC) Oncotarget Volume 11 Issue 8 features Figure 8, 'MLN4924 treatment induces DNA damage by stabilizing CDT1 and accumulates the cells in S phase which are enhanced by MLN4924/cisplatin co-treatment,' by Misra, et al.